JP5252922B2 - 遺伝的改変についてホモ接合性の動物を生み出すための方法 - Google Patents

遺伝的改変についてホモ接合性の動物を生み出すための方法 Download PDF

Info

Publication number
JP5252922B2
JP5252922B2 JP2007537999A JP2007537999A JP5252922B2 JP 5252922 B2 JP5252922 B2 JP 5252922B2 JP 2007537999 A JP2007537999 A JP 2007537999A JP 2007537999 A JP2007537999 A JP 2007537999A JP 5252922 B2 JP5252922 B2 JP 5252922B2
Authority
JP
Japan
Prior art keywords
mouse
embryo
cells
cell
genetic modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007537999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516633A5 (enExample
JP2008516633A (ja
Inventor
ウィリアム ポウイーミロウ
トーマス エム． デチアラ
ウォジテック アウアーバッハ
デイヴィッド フレンドウェイ
デイヴィッド エム． ヴァレンズエラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2008516633A publication Critical patent/JP2008516633A/ja
Publication of JP2008516633A5 publication Critical patent/JP2008516633A5/ja
Application granted granted Critical
Publication of JP5252922B2 publication Critical patent/JP5252922B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2007537999A 2004-10-19 2005-10-19 遺伝的改変についてホモ接合性の動物を生み出すための方法 Expired - Lifetime JP5252922B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61999904P 2004-10-19 2004-10-19
US60/619,999 2004-10-19
US68919205P 2005-06-10 2005-06-10
US60/689,192 2005-06-10
PCT/US2005/037584 WO2006044962A1 (en) 2004-10-19 2005-10-19 Method for generating an animal homozygous for a genetic modification

Publications (3)

Publication Number Publication Date
JP2008516633A JP2008516633A (ja) 2008-05-22
JP2008516633A5 JP2008516633A5 (enExample) 2008-11-27
JP5252922B2 true JP5252922B2 (ja) 2013-07-31

Family

ID=35511302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537999A Expired - Lifetime JP5252922B2 (ja) 2004-10-19 2005-10-19 遺伝的改変についてホモ接合性の動物を生み出すための方法

Country Status (12)

Country Link
US (7) US7294754B2 (enExample)
EP (2) EP1802193B1 (enExample)
JP (1) JP5252922B2 (enExample)
AU (1) AU2005295269B2 (enExample)
CA (2) CA2583750C (enExample)
CY (1) CY1120496T1 (enExample)
DK (2) DK1802193T3 (enExample)
ES (2) ES2667169T3 (enExample)
PL (2) PL1802193T3 (enExample)
PT (2) PT2767161T (enExample)
SI (1) SI1802193T1 (enExample)
WO (1) WO2006044962A1 (enExample)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802193B1 (en) * 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US7740159B2 (en) * 2006-08-02 2010-06-22 Ethicon Endo-Surgery, Inc. Pneumatically powered surgical cutting and fastening instrument with a variable control of the actuating rate of firing with mechanical power assist
TWI476280B (zh) * 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
EP3417701B1 (en) * 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
EP3336102A3 (en) 2009-12-21 2018-08-01 Regeneron Pharmaceuticals, Inc. Humanized fc gamma r mice
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
WO2011156723A1 (en) 2010-06-11 2011-12-15 Regeneron Pharmaceuticals, Inc. Production of fertile xy female animals from xy es cells
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
SI2480676T1 (sl) 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
WO2012092284A1 (en) 2010-12-27 2012-07-05 The Jackson Laboratory Compositions and methods relating to non-human animals modified to promote production of selected gametes
RU2577978C2 (ru) 2011-02-15 2016-03-20 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
DK2813573T1 (da) 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
ES2541535T3 (es) 2011-05-12 2015-07-21 Regeneron Pharmaceuticals, Inc. Ensayo de liberación de neuropéptido para canales de sodio
WO2012168399A1 (en) 2011-06-08 2012-12-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting, treating and modelling hormone resistance
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
KR102295746B1 (ko) 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CN104011071B (zh) 2011-10-28 2017-11-07 瑞泽恩制药公司 T细胞受体基因修饰小鼠
SG10201510056SA (en) 2011-10-28 2016-01-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9381518B2 (en) 2011-10-31 2016-07-05 Merck Sharp & Dohme Corp. Nano-suspension process
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
MX378871B (es) 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
WO2013096562A1 (en) 2011-12-22 2013-06-27 E. I. Du Pont De Nemours And Company Use of the soybean sucrose synthase promoter to increase plant seed lipid content
PL2809150T3 (pl) 2012-02-01 2020-04-30 Regeneron Pharmaceuticals, Inc. Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
AU2013204140B2 (en) 2012-03-06 2016-01-28 Regeneron Pharmaceuticals, Inc. Common light chain mouse
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP6275120B2 (ja) 2012-04-25 2018-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 大きい標的化ベクターによるヌクレアーゼ媒介標的化
EP2858487B1 (en) 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
NZ746089A (en) 2012-09-07 2020-05-29 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
JP6475172B2 (ja) 2013-02-20 2019-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットの遺伝子組換え
JP6444321B2 (ja) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
WO2014164640A1 (en) 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
AU2014249148B2 (en) 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
PT3501272T (pt) 2013-03-13 2023-03-29 Regeneron Pharma Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina
RU2015143108A (ru) 2013-03-13 2017-04-20 Регенерон Фарматютикалз, Инк. Мышь с общей легкой цепью
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
JP6689498B2 (ja) * 2013-04-16 2020-04-28 イーエムべーアー−インスティツート フューア モレクラー ビオテクノロギー ゲーエムベーハー ブラストイド、細胞株に基づく人工胚盤胞
EP3456831B1 (en) 2013-04-16 2021-07-14 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
IL294443A (en) 2013-08-07 2022-09-01 Regeneron Pharma Lincrna-deficient non-human animals
KR102150414B1 (ko) 2013-09-18 2020-09-02 리제너론 파마슈티칼스 인코포레이티드 히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
NZ719493A (en) 2013-11-07 2020-02-28 Ozgene Holdings Pty Ltd Compositions and methods for producing genetically modified animals
EP3071024B1 (en) 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EP3430898A1 (en) 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
ES2975317T3 (es) * 2013-12-11 2024-07-04 Regeneron Pharma Métodos y composiciones para la modificación dirigida de un genoma
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
BR112016026245A2 (pt) 2014-05-30 2018-02-20 Regeneron Pharma ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor?
BR112016028564A2 (pt) 2014-06-06 2018-01-30 Regeneron Pharma método para modificar um locus-alvo em uma célula.
DK3157956T3 (da) 2014-06-19 2020-04-27 Regeneron Pharma Ikke-humane dyr med et humaniseret gen med programmeret celledød 1
SG10201911411YA (en) 2014-06-26 2020-02-27 Regeneron Pharma Methods and compositions for targeted genetic modifications and methods of use
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
CA2963315A1 (en) 2014-10-15 2016-04-21 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
CA3176380A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017010793A2 (pt) 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
ES2969389T3 (es) 2014-12-05 2024-05-17 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
EP4399969A3 (en) 2014-12-09 2024-10-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
BR112017013104A2 (pt) 2014-12-19 2018-05-15 Regeneron Pharma métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
BR112017019620A2 (pt) 2015-03-16 2018-05-15 Regeneron Pharmaceuticals, Inc. ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor?
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016246698B2 (en) 2015-04-06 2022-06-02 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals
SG10202103445QA (en) 2015-04-13 2021-05-28 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof
ES2784360T3 (es) 2015-05-29 2020-09-24 Regeneron Pharma Animales no humanos que tienen una interrupción en un locus C9ORF72
EP3310159B1 (en) 2015-06-16 2024-10-09 The Jackson Laboratory Genetically modified mice and methods relating to complement dependent cytotoxicity
EP3344034A1 (en) 2015-09-02 2018-07-11 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
JP6868615B2 (ja) 2015-09-17 2021-05-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 繁殖可能なｘｙ雌マウスを生成するための多能性細胞の選択
PT3376857T (pt) 2015-11-20 2021-05-27 Regeneron Pharma Animais não humanos com um gene humanizado 3 de ativação de linfócitos
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
US10582702B2 (en) 2016-02-04 2020-03-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
EP3416479A1 (en) 2016-02-16 2018-12-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
CA3014645C (en) 2016-02-29 2022-10-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
BR112019001783A2 (pt) 2016-07-29 2019-05-07 Regeneron Pharmaceuticals, Inc. mamífero não humano, e, métodos para produzir o mamífero não humano e de triagem de um composto.
EP4056031A1 (en) 2016-08-11 2022-09-14 The Jackson Laboratory Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
US10781453B2 (en) 2016-09-30 2020-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus
EP3532493B1 (en) 2016-10-27 2023-04-26 The Jackson Laboratory Genetically modified mouse model for human hepatocyte xenotransplantation
JP7458185B2 (ja) 2016-11-30 2024-03-29 ザ ジャクソン ラボラトリー 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル
SG10202109874VA (en) 2017-01-19 2021-10-28 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US11064685B2 (en) 2017-02-27 2021-07-20 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
WO2018175581A1 (en) 2017-03-21 2018-09-27 The Jackson Laboratory A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF
SG10202112528QA (en) 2017-05-12 2021-12-30 Jackson Lab Nsg mice lacking mhc class i and class ii
KR20240135035A (ko) 2017-06-27 2024-09-10 리제너론 파마슈티칼스 인코포레이티드 인간화 asgr1 유전자좌를 포함하는 비인간 동물
KR102780441B1 (ko) 2017-07-31 2025-03-17 리제너론 파마슈티칼스 인코포레이티드 Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
RU2019143568A (ru) 2017-07-31 2021-09-02 Регенерон Фармасьютикалс, Инк. Способы и композиции для оценки crispr/cas-индуцированной рекомбинации с экзогенной донорной нуклеиновой кислотой in vivo
KR20200033259A (ko) 2017-07-31 2020-03-27 리제너론 파마슈티칼스 인코포레이티드 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
IL272475B2 (en) 2017-08-09 2025-05-01 Jackson Lab Immunodeficient mice expressing interleukin 15
CN111386039B (zh) 2017-09-29 2023-02-28 瑞泽恩制药公司 经基因修饰的啮齿动物基因组
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
CN111565566B (zh) 2017-11-10 2022-10-21 瑞泽恩制药公司 包含slc30a8突变的非人动物及使用方法
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
CN111885915B (zh) 2018-03-19 2023-04-28 瑞泽恩制药公司 使用crispr/cas系统对动物进行转录调制
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
JP7420730B2 (ja) 2018-04-06 2024-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
US10463029B1 (en) 2018-06-07 2019-11-05 Regeneron Pharmaceuticals, Inc. Rodent model of steel syndrome
AU2019284762A1 (en) 2018-06-13 2020-11-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
WO2019246483A1 (en) 2018-06-21 2019-12-26 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
HUE067361T2 (hu) 2018-07-16 2024-10-28 Regeneron Pharma Ditra betegség rágcsáló modelljei és alkalmazásaik
ES2974200T3 (es) 2018-09-13 2024-06-26 Regeneron Pharma Rata nuligénica para el gen del factor H del complemento como modelo de glomerulopatía C3
KR20210104744A (ko) 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
KR20210105914A (ko) 2018-12-20 2021-08-27 리제너론 파마슈티칼스 인코포레이티드 뉴클레아제-매개 반복부 팽창
US11470828B2 (en) 2019-01-17 2022-10-18 Regeneran Pharmaceuticals, Inc. Rodent model of mood disorders
WO2020152607A1 (en) 2019-01-22 2020-07-30 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
SG11202109407XA (en) 2019-03-15 2021-09-29 Regeneron Pharma A loss of function rodent model of solute carrier 39 member 5
AU2020253532B2 (en) 2019-04-04 2024-06-20 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
PH12021552675A1 (en) 2019-05-13 2022-07-04 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CA3136478A1 (en) 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
SG11202111256XA (en) 2019-06-07 2021-11-29 Regeneron Pharma Non-human animals comprising a humanized albumin locus
PH12021552903A1 (en) 2019-06-11 2022-04-04 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
WO2020264339A1 (en) 2019-06-27 2020-12-30 Regeneron Pharmaceuticals, Inc. Modeling tdp-43 proteinopathy
CA3153141A1 (en) 2019-10-03 2021-04-08 Regeneron Pharmaceuticals, Inc. A crnn loss of function rodent model
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
BR112022011417A2 (pt) 2019-12-13 2022-08-30 Alnylam Pharmaceuticals Inc Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
JP2023511626A (ja) 2020-01-28 2023-03-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法
WO2021158883A1 (en) 2020-02-07 2021-08-12 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
IL295080A (en) 2020-03-04 2022-09-01 Regeneron Pharma A rodent model of b4galt1-mediated functions
EP4125348A1 (en) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
JP7765403B2 (ja) 2020-04-21 2025-11-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物
RU2751237C1 (ru) * 2020-06-10 2021-07-12 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
WO2021263146A2 (en) 2020-06-26 2021-12-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
EP4221496A1 (en) 2020-10-01 2023-08-09 Regeneron Pharmaceuticals, Inc. Rodent animals expressing human cr1
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN116802200A (zh) 2020-12-21 2023-09-22 瑞泽恩制药公司 具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物
IL307238A (en) 2021-03-31 2023-11-01 Regeneron Pharma Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire
WO2023081847A1 (en) 2021-11-04 2023-05-11 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified cacng1 locus
CA3238939A1 (en) 2021-12-08 2023-06-15 Gaurang Patel Mutant myocilin disease model and uses thereof
US20250049006A1 (en) 2021-12-20 2025-02-13 C/O Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
EP4475671A1 (en) 2022-02-07 2024-12-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
CA3242729A1 (en) 2022-02-11 2023-08-17 Regeneron Pharma Compositions and methods for screening 4r tau targeting agents
WO2023212560A1 (en) 2022-04-26 2023-11-02 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
WO2023235677A1 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Animal model of tdp-43 proteinopathy
US20230417899A1 (en) 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
KR20250048010A (ko) 2022-07-29 2025-04-07 리제너론 파마슈티칼스 인코포레이티드 변형된 트랜스페린 수용체 좌위를 포함하는 비-인간 동물
CA3261296A1 (en) 2022-08-05 2024-02-08 Regeneron Pharma TDP-43 VARIANTS RESISTANT TO AGGREGATION
EP4590120A1 (en) 2022-09-22 2025-07-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
EP4658066A1 (en) 2023-02-01 2025-12-10 Regeneron Pharmaceuticals, Inc. Animals comprising a modified klhdc7b locus
KR20250155054A (ko) 2023-03-13 2025-10-29 리제너론 파마슈티칼스 인코포레이티드 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
CN116445396B (zh) * 2023-04-07 2025-03-25 中国农业大学 一种wnt2用于提高体外受精胚胎发育效率和质量的新用途
WO2024259354A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025006963A1 (en) 2023-06-30 2025-01-02 Regeneron Pharmaceuticals, Inc. Methods and compositions for increasing homology-directed repair
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2025122669A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized complement factor b gene
WO2025122754A1 (en) 2023-12-07 2025-06-12 Regeneron Pharmaceuticals, Inc. Gaa knockout non-human animals
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025226695A1 (en) 2024-04-23 2025-10-30 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
AUPP421298A0 (en) * 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
US6485972B1 (en) * 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
US6784336B2 (en) * 2000-09-20 2004-08-31 Whitehead Institute For Biomedical Research Method of producing mutant mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1383867A2 (en) * 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
DE60301953T2 (de) * 2002-03-05 2006-07-27 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
JP2006345702A (ja) 2003-08-05 2006-12-28 Tanabe Seiyaku Co Ltd 胚性幹細胞の未分化状態の維持剤
WO2005113751A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification

Also Published As

Publication number Publication date
CA2827654C (en) 2019-04-02
SI1802193T1 (sl) 2014-08-29
CA2827654A1 (en) 2006-04-27
EP1802193A1 (en) 2007-07-04
CA2583750C (en) 2015-11-24
DK1802193T3 (da) 2014-06-10
US7294754B2 (en) 2007-11-13
US7659442B2 (en) 2010-02-09
DK2767161T3 (en) 2018-05-07
US20160316729A1 (en) 2016-11-03
ES2463476T3 (es) 2014-05-28
US20080078001A1 (en) 2008-03-27
US20140331340A1 (en) 2014-11-06
US9414575B2 (en) 2016-08-16
WO2006044962A1 (en) 2006-04-27
PT1802193E (pt) 2014-06-23
US20170295762A1 (en) 2017-10-19
US20060085866A1 (en) 2006-04-20
PL2767161T3 (pl) 2018-09-28
CY1120496T1 (el) 2019-07-10
PT2767161T (pt) 2018-04-20
US10039269B2 (en) 2018-08-07
US7576259B2 (en) 2009-08-18
AU2005295269A1 (en) 2006-04-27
US8816150B2 (en) 2014-08-26
US9730434B2 (en) 2017-08-15
HK1200269A1 (en) 2015-08-07
EP2767161A1 (en) 2014-08-20
ES2667169T3 (es) 2018-05-09
JP2008516633A (ja) 2008-05-22
PL1802193T3 (pl) 2014-09-30
US20080078000A1 (en) 2008-03-27
US20080028479A1 (en) 2008-01-31
EP2767161B1 (en) 2018-02-07
CA2583750A1 (en) 2006-04-27
EP1802193B1 (en) 2014-04-30
AU2005295269B2 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
JP5252922B2 (ja) 遺伝的改変についてホモ接合性の動物を生み出すための方法
Madeja et al. Beyond the mouse: Non-rodent animal models for study of early mammalian development and biomedical research
Tokunaga et al. Efficacious Production of Viable Germ‐Line Chimeras between Embryonic Stem (ES) Cells and 8‐Cell Stage Embryos: (embryonic stem cell/mouse embryo chimera/germ line transmission)
JP2008516633A5 (enExample)
JP2000516463A (ja) 特定の遺伝的特性を有する哺乳動物を作製する方法
EP2215232A2 (en) Method of genetically altering and producing allergy free cats
JP6827250B2 (ja) 多能性幹細胞再樹立法
US20170107540A1 (en) Method of genetically altering and producing allergy free cats
Kondoh et al. Easy assessment of ES cell clone potency for chimeric development and germ-line competency by an optimized aggregation method
WO2006009297A1 (ja) Es細胞を用いたキメラ作製
HK1200269B (en) Method for generating an non-human animal homozygous for a genetic modification
Gardner Pluripotent stem cells from vertebrate embryos: present perspective and future challenges
Gardner Pluripotential stem cells from vertebrate embryos: present perspective and future challenges
CN119913110A (zh) 利用胚胎干细胞产生高比例嵌合的活体猴的方法
Ladiges et al. Transgenic animals in toxicology
Gardner Present perspective and future challenges
Illmensee Genetic manipulation of the early mouse embryo
ISHIKAWA et al. Production of Medaka chimeras from in vitro cultured embryonic cells

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20081007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130416

R150 Certificate of patent or registration of utility model

Ref document number: 5252922

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160426

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250